

Table 1: ART policies in 114 countries (Last updated: May 2016). This list is contingent upon publication or published national guidelines.

	2003-05	2006-08	2009	2010	2011	2012	2013	2014	2015
Irrespective of CD4 count						Netherlands, USA DHHS	Australia, Brazil, France, South Korea, Turkey	Mexico, Romania, Spain, Thailand	Argentina, Britain, Maldives
≤500 (consider for ≥500)	USA DHHS			Italy			Hong Kong		
≤500				Algeria			WHO, Bolivia, Chile, Colombia, Democratic Republic of Congo, Ecuador, Ethiopia, Fiji, Haiti, Honduras, Madagascar, Mali, Oman, Rwanda, Tunisia, Uganda, Zambia, Zimbabwe	WHO, Bangladesh, Bhutan, Burundi, Nepal, Cameroon, Gabon, El Salvador, Kenya, Lesotho, Malawi, Mauritania, Myanmar, Namibia, Sudan, Poland, South Africa, South Sudan, Sri Lanka, Tanzania, Uruguay, Venezuela	WHO, Cambodia, Pakistan, Swaziland, Viet Nam
≤350 (consider for ≤500)			Guyana*		Guinea	Belize		Austria*, Costa Rica, Finland, Germany*, Greece*, Norway*	
≤350		Burkina Faso, Djibouti, Ghana, Sierra Leone	Croatia, Niger, Moldova, Papua New Guinea, Portugal, Nicaragua, Sweden	WHO, Morocco, Nigeria, Ukraine	WHO, Jamaica, Kazakhstan, Panama, Switzerland, Timor-Leste	WHO, Botswana, Benin, China, Guatemala, Peru	Canada, Cote d'Ivoire, Dominican Republic, India, Paraguay	Angola, Indonesia, Latvia, Malaysia, Mozambique	
≤300		Macedonia							
≤200 (consider for ≤350)	Cape Verde, Estonia	WHO, Afghanistan, Belarus, Russia	WHO, Cuba						
≤200	WHO, Senegal	Comoros, Lao People's Democratic Republic, Liberia	Philippines						

*Austria, Germany, Greece, Guyana and Norway additionally recommend *considering* ART at CD4 count ≥ 500 cells/mm³.

Countries in grey boxes are consistent with WHO guidelines in a given year while countries in bold were recommended early ART compared to WHO recommendation.